ParcelBio | LinkedIn (original) (raw)
Biotechnology Research
San Francisco, California 757 followers
Programmable delivery of mRNA medicines
About us
ParcelBio is developing a programmable technology to safely and specifically deliver mRNA to diverse cell types in the body. Our proprietary (nanoparticle-free) technology, which we call ‘STAmP’, stabilizes the mRNA and utilizes an interchangeable, lock-and-key-like targeting mechanism which enables fully customizable mRNA medicines.
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
San Francisco, California
Type
Privately Held
Founded
2023
Locations
Employees at ParcelBio
Updates
- We are excited to be working with Surbhi Sarna and have the backing of Y Combinator!
Group Partner at Y Combinator | Author of Without a Doubt | Founder of nVision (now part of NYSE: BSX) | Board Director | Grape Grower
8mo
This YC batch represents the most impressive group of biotech founders I have worked with. If any one of them succeeds, the face of medicine will change for the better. But the thing is, they’re so talented and hardworking -- I can see multiple game-changing medicines from this one group making it to the market. They’re doing things like producing experimental data in record time, attracting world-class advisors like the founding CSO of Moderna, to working on radically new approaches to treat cancer. I couldn’t be more thrilled to be working with the following companies this batch: Two long-time friends and Ph.D.s from Oxford have started Granza. Granza Bio is developing cancer therapeutics called "attack particles,” derived from our body’s immune system. These "attack particles" selectively target and kill only cancer cells, eliminating toxicity from cancer treatment. The team has obtained cancer-killing efficacy data in models of ovarian, brain, lung, and skin cancers. Dr Ashwin Menon NandakumarFriends and co-authors on multiple publications, this dual women founder team started Eris. Eris Biotech develops cancer drugs that target tumors without poisoning the rest of the body. Their first drug, which only activates under low oxygen environments- a hallmark of solid tumors- is designed to treat mesothelioma. Evita Weagel, Ph.D.These two friends were colleagues/leaders in the space before leaving the comfortable life of industry to embark on their start-up. ParcelBio is an mRNA therapeutics company addressing the “delivery problem.” Their programmable technology enables the safe, specific, and efficient delivery of mRNA medicines to diverse cell types in the body—without a nanoparticle. David WeinbergIf you’re lucky enough to speak to these two, you will not believe that this medical school drop outs are only 22. Wise beyong their years, they started Velorum. Velorum Therapeutics is developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism. They have shown that their drugs work in mice and plan to begin human clinical trials next year, starting with the #1 cancer killer – lung cancer. Pouya ModareszadehThese brilliant boston based founders started Synsory. At SynsoryBio, they engineer "if-then" conditional logic into protein medicines, meaning only if the protein drug senses a disease marker, then it turns on. They are applying this technology to clinically tested but highly toxic cancer immunotherapies to make them safer and more effective. Elliot TagueSelera Medical is a bit different from the rest – they met at Stanford and have created a medical device that can cure hearth failure with a one time treatment, which would be both groundbreaking for patients as well as our healthcare system, which spends a tremendous amount of money on heart failure. Stacie Arechavala - ParcelBio reposted this
ParcelBio (YC W24) is addressing the biggest problem in RNA therapeutics: delivery. They are developing a programmable technology to safely and specifically deliver mRNA to diverse cell types in the body. mRNA is a versatile therapeutic: It can be programmed to produce just about anything the body could need. The key hurdle limiting the full therapeutic potential of mRNA is delivery; it’s hard to get enough mRNA exactly where it needs to go. To safely and efficiently deliver an mRNA therapeutic requires a delivery vehicle that imparts two features: stability and targeting. The current delivery vehicle of choice is a lipid nanoparticle (LNP), which is essentially a fat droplet that encapsulates the mRNA. LNPs work great for vaccines, but applications beyond vaccines require more specific targeting and higher doses than what best-in-class LNP technologies can provide. Founded by David Weinberg and Christopher Carlson, ParcelBio’s proprietary technology, ‘STAmP’ (Stabilization and Targeting by Annealing mRNA to ParcelOligos), is a completely new way of delivering an mRNA medicine (without a nanoparticle). STAmP’s key innovation is the use of ParcelOligos, which binds to an mRNA molecule to convert it into a more stable form so that it can survive the journey to desired cell types. In addition to imparting stability, ParcelOligos enables cell-specific targeting by incorporating interchangeable ‘keys’ that only unlock cells with the corresponding lock. Their first drugs will address chronic liver diseases, kidney disorders, and immune system dysregulation—and that's just the beginning. Congrats on the launch, David and Chris — and welcome to YC!
Launch YC: ParcelBio: Programmable delivery of mRNA medicines | Y Combinator ycombinator.com